HIV-HBV coinfection among South African patients receiving antiretroviral therapy.
There are approximately 33 million individuals with HIV infection worldwide. The majority of infections are in southern Africa where hepatitis B is also known to be endemic. As access to life-saving antiretroviral therapy (ART) increases, the possibility for hepatitis B treatment resistance increases because most ART regimens contain lamivudine. Patients coinfected with HBV are therefore receiving monotherapy for HBV infection, leading to possible HBV-resistant mutants and the concurrent public health effect thereof. Additional information is needed on the prevalence of HIV-HBV coinfection and treatment response to ART. We present a summary of the information available from South Africa to date.
Di Bisceglie
Adrian M
AM
Department of Internal Medicine, Saint Louis University, St Louis, MO, USA. dibiscam@slu.edu
Maskew
Mhairi
M
Schulze
Doreen
D
Reyneke
Anne
A
McNamara
Lynne
L
Firnhaber
Cindy
C
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D006509:Hepatitis B / Q000150:complications / Q000453:epidemiology / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D015995:Prevalence; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013019:South Africa / Q000453:epidemiology
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine